These three companies have the potential to double their share price from current levels. Here's why.
In the multibillion-dollar market for hepatitis C, this company stands above the crowd.
Healthcare stocks with plenty of potential -- and low share prices
AbbVie is reportedly still interested in acquiring additional assets to help it over the Humira patent cliff hump. Would Acadia Pharmaceuticals be a good match for this big pharma?
Will Actavis' $66 billion merger with Allergan catapult this company from good to great? Or could a hidden risk derail this global powerhouse?
Safe biotech? No such thing. But this behemoth biotech just might be the safest bet out there.
Coherus BioSciences shares are dropping on news tied to a dilutive share offering.
Our experts weigh in.
Prices for cancer medications are soaring.
With the regulatory pathway cleared, the biosimilars market is poised to turn into a gold mine, growing up to 6,250% in 10 years. Here's where to stake your claim.